JP2017509585A5 - - Google Patents

Download PDF

Info

Publication number
JP2017509585A5
JP2017509585A5 JP2016541595A JP2016541595A JP2017509585A5 JP 2017509585 A5 JP2017509585 A5 JP 2017509585A5 JP 2016541595 A JP2016541595 A JP 2016541595A JP 2016541595 A JP2016541595 A JP 2016541595A JP 2017509585 A5 JP2017509585 A5 JP 2017509585A5
Authority
JP
Japan
Prior art keywords
formula
salt
compound
providing
crystal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016541595A
Other languages
English (en)
Japanese (ja)
Other versions
JP6425727B2 (ja
JP2017509585A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/071319 external-priority patent/WO2015100145A1/en
Publication of JP2017509585A publication Critical patent/JP2017509585A/ja
Publication of JP2017509585A5 publication Critical patent/JP2017509585A5/ja
Application granted granted Critical
Publication of JP6425727B2 publication Critical patent/JP6425727B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016541595A 2013-12-23 2014-12-18 大環状hcv ns3阻害トリペプチド Active JP6425727B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361920446P 2013-12-23 2013-12-23
US61/920,446 2013-12-23
PCT/US2014/071319 WO2015100145A1 (en) 2013-12-23 2014-12-18 Synthesis of a macrocyclic hcv ns3 inhibiting tripeptide

Publications (3)

Publication Number Publication Date
JP2017509585A JP2017509585A (ja) 2017-04-06
JP2017509585A5 true JP2017509585A5 (enExample) 2018-01-18
JP6425727B2 JP6425727B2 (ja) 2018-11-21

Family

ID=52278856

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016541595A Active JP6425727B2 (ja) 2013-12-23 2014-12-18 大環状hcv ns3阻害トリペプチド

Country Status (20)

Country Link
US (2) US9440991B2 (enExample)
EP (1) EP3087085B1 (enExample)
JP (1) JP6425727B2 (enExample)
KR (1) KR102366697B1 (enExample)
CN (3) CN105849118B (enExample)
AR (1) AR098959A1 (enExample)
AU (1) AU2014370125B2 (enExample)
CA (1) CA2934537C (enExample)
EA (1) EA201691031A1 (enExample)
ES (1) ES2724460T3 (enExample)
IL (1) IL246064A0 (enExample)
MX (1) MX2016008452A (enExample)
NZ (1) NZ720745A (enExample)
PL (1) PL3087085T3 (enExample)
PT (1) PT3087085T (enExample)
SG (1) SG11201604482QA (enExample)
SI (1) SI3087085T1 (enExample)
TR (1) TR201906413T4 (enExample)
TW (3) TWI671292B (enExample)
WO (1) WO2015100145A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2822285T3 (es) 2013-07-30 2021-04-30 Kronos Bio Inc Polimorfo de inhibidores de SYK
MD4684B1 (ro) 2013-07-30 2020-03-31 Gilead Connecticut INc. Formulări pe bază de imidazopirazine în calitate de inhibitori SYK
TR201906413T4 (tr) 2013-12-23 2019-05-21 Gilead Sciences Inc Bir makrosiklik hcv ns3 inhibe edici tripeptidin sentezi.
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
US9809576B1 (en) 2014-07-18 2017-11-07 Abbvie Inc. Synthetic route to anti-viral agents
US9809534B1 (en) * 2014-07-21 2017-11-07 Abbvie Inc. Difluoroalkylcyclopropyl amino acids and esters, and syntheses thereof
US10059969B1 (en) 2014-10-03 2018-08-28 Abbvie Inc. Process for the preparation of (S)-2-amino-non-8-enoic acid
US10316338B1 (en) 2015-01-30 2019-06-11 Abb Vie Inc. Enzymatic process for the preparation of (1S,2R)-2-(difluoromethyl)-1-(propoxycarbonyl)cyclopropanecarboxylic acid
EP3315497B1 (en) 2015-06-29 2020-01-08 Central Glass Company, Limited Method for producing fluorine-containing cyclopropane carboxylic acid compound
TWI693286B (zh) 2017-02-01 2020-05-11 美商艾伯維有限公司 (±)-2-(二氟甲基)-1-(烷氧羰基)-環丙烷甲酸及(±)-2-(乙烯基)-1-(烷氧羰基)-環丙烷甲酸之酶催化製法
WO2019084740A1 (zh) * 2017-10-31 2019-05-09 上海同昌生物医药科技有限公司 一种Glecaprevir合成中间体及其胺盐的制备方法
CN107739319A (zh) * 2017-10-31 2018-02-27 上海同昌生物医药科技有限公司 一种Glecaprevir合成中间体及其胺盐的制备方法
CN107827748A (zh) * 2017-11-14 2018-03-23 安徽华胜医药科技有限公司 一种乙酸2‑烯丙基环丙酯消旋体的合成方法
KR102519417B1 (ko) 2018-11-28 2023-04-10 삼성디스플레이 주식회사 스트레처블 표시 장치
US11339168B2 (en) 2019-02-22 2022-05-24 Kronos Bio, Inc. Crystalline forms of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as Syk inhibitors
CN116041181A (zh) * 2023-01-04 2023-05-02 广州巨元生化有限公司 一种制备4-卤代-2-甲基-2-丁烯酸烃基酯的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200605247B (en) * 2003-12-15 2007-10-31 Japan Tobacco Inc N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof
CL2008003384A1 (es) * 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
WO2009134987A1 (en) 2008-04-30 2009-11-05 Enanta Pharmaceuticals, Inc. Difluoromethyl-containing macrocyclic compounds as hepatitis c virus inhibitors
SI2540350T1 (sl) * 2008-07-22 2015-01-30 Merck Sharp & Dohme Corp. Kombinacije makrocikliäśnih kinoksalinske spojine, ki je hcv ns3 proteazni inhibitor z drugimi hcv uäśinkovinami
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2289880A1 (en) * 2009-07-08 2011-03-02 Bayer CropScience AG 2-Pyridinylcyclopropylbenzamide fungicides
WO2012040040A1 (en) * 2010-09-21 2012-03-29 Merck Sharp & Dohme Corp. Hcv ns3 protease inhibitors
BR112013006693B1 (pt) * 2010-09-21 2022-07-12 Enanta Pharmaceuticals, Inc Compostos inibidores da serino protease hcv derivada de prolina macrocíclica
UY33775A (es) * 2010-12-10 2012-07-31 Gilead Sciences Inc Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos
UA119315C2 (uk) * 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
WO2015095430A1 (en) * 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Methods and intermediates for the preparation of macrolactams
WO2015100144A1 (en) * 2013-12-23 2015-07-02 Gilead Sciences, Inc. Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide
TR201906413T4 (tr) 2013-12-23 2019-05-21 Gilead Sciences Inc Bir makrosiklik hcv ns3 inhibe edici tripeptidin sentezi.

Similar Documents

Publication Publication Date Title
JP2017509585A5 (enExample)
JP2016520672A5 (enExample)
ME02861B (me) Postupak za pripremu treprostinila i njegovih derivata
JP2010043124A5 (enExample)
EP3056486A3 (en) Process for preparing intermediates for antiviral compounds
JP2011126894A5 (enExample)
JP2010530373A5 (enExample)
MX2013000295A (es) Procedimiento de preparacion de un inhibidor especifico de la trombina.
GB201110520D0 (en) Extraction of carboxylic acids with tin compounds
AR098959A1 (es) Síntesis de un compuesto antiviral e intermediarios de la misma
JP2017524742A5 (enExample)
JO3263B1 (ar) مشتق إندان سلفاميد جديد
AR088296A1 (es) Citramida de rasagilina, proceso de preparación y composicion farmaceutica
RU2017145357A (ru) Пролекарство на основе фосфамида монобензилового сложного эфира тенофовира, способ его получения и применение
EP2736860A4 (en) METHOD FOR THE PRODUCTION OF AROMATIC HYDROCARBONS FROM BYPRODUCTS OF AROMATIC CARBOXYLIC ACID AND / OR METHOD FOR THE PRODUCTION OF AN AROMATIC CARBOXYLIC ALKYL REAGER
JP2014506185A5 (enExample)
EP2665705A4 (en) PROCESS FOR THE IMPROVED PREPARATION OF SUCCINIMIDE COMPLEXES OF MOLYBDENUM OF LOW MOLECULAR WEIGHT
JP2016523246A5 (enExample)
SA112330457B1 (ar) مشتقات فينيل- ايزواوكسازول وعملية تحضيرها
MX360161B (es) Proceso para preparar compuestos antiviricos.
EP2684859A4 (en) PROCESS FOR PREPARING FLUOROUS OLEFINS WITH SUBSTITUENTS FROM ORGANIC GROUPS
AR081267A1 (es) Procedimiento de obtencion de la forma cristalina a del febuxostat
JP2016517904A5 (enExample)
EA201790659A1 (ru) Способ получения сложных эфиров карбоновых кислот в присутствии титансодержащего катализатора
WO2014136047A3 (en) A process for the preparation of 2-amino-1,3-propane diol compounds and salts thereof